- Late Payments on Credit Cards Drop in Third Quarter
- Little Sign of Inflation on the Horizon: IMF
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Wall Street Finds Profits by Reducing Mortgages
- Microsoft, News Corp Weigh Online News Pact
- Warren Buffett, Bill Gates 'Walk & Talk' At Columbia
- 10 Tips to Get Out of Debt
- Thanksgiving Week Stuffed With Economic News
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
Text Size 
The director of the FDA's division of antiviral products is urging caution in the use of a new flu drug that just won special permission to fight H1N1.
Two weeks ago the FDA gave Emergency Use Authorization for the IV drug peramivir from BioCryst Pharmaceuticals [BCRX
Loading...
()
].
The EUA allows doctors to ask the CDC for access to the drug for use only on certain hospitalized pediatric and adult patients.
But the FDA's Dr. Debra Birnkrant, in an Op-Ed piece in "The New England Journal of Medicine" writes, "Alternatives should be considered."
She points out that peramivir remains formally unapproved and adds, "No conclusions about efficacy can be drawn" from previous studies of peramivir on the seasonal flu.
"There are very limited data available regarding the use of peramivir in seriously ill hospitalized patients," Dr. Birnkrant writes.
Peramivir is the third flu-fighting drug available to combat H1N1, but is the only IV treatment. Roche [RHBBY
Loading...
()
] and Gilead Sciences [GILD
Loading...
()
] are behind the most popular remedy, Tamiflu. GlaxoSmithKline [GSK
Loading...
()
] makes the smaller-selling inhalable Relenza.
In an email, a BioCryst spokesman tells CNBC the NEJM article "should help improve awareness of peramivir and the EUA in the medical community. Hopefully, peramivir will reach a greater portion of hospitalized patients...." The company says it's prepared to deliver up to 130,000 courses of the drug by the end of this year.
Print
Email
- Technology can make or break a fortune in the world of alternative energy.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes